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Abstract
Introduction: Smoking increases the risk of developing rheumatoid arthritis (RA) and affects the severity of
established RA. Smoking can impact on Th17 lymphocyte differentiation and function through activation of the
aryl hydrocarbon receptor (AHR), a process with implications for the pathogenic mechanisms in RA that involve the
cytokine, interleukin (IL)-17A. The objective of this study was to establish any effect of smoking on the
inflammatory tissue lesions of rheumatoid arthritis via the AHR and IL-17A.
Methods: Twenty synovial and eighteen subcutaneous nodule tissue samples from 31 patients with RA were
studied. Patient smoking status at the time of tissue collection was established. Expression of AHR, CYP1A1, AHRR,
IL6, IL17A, IL17F, IL22, IL23, IL23R, IFNG, TBX21, IDO1 and FOXP3 genes were assessed in tissues and cultured cells
using real-time PCR. Two-colour immunofluorescence was used to co-localise AHR and CYP1A1 protein in synovial
tissues. The response of monocytes and monocyte-derived dendritic cells (mo-DCs) to the AHR agonist, benzo(a)
pyrene (BaP) was compared in vitro.
Results: AHR gene expression was demonstrated in rheumatoid synovial tissues and nodules with significantly
greater expression in synovia. Expression was not influenced by smoking in either tissue. Evidence of AHR
activation, indicated by CYP1A1 and AHRR gene expression, was found only in synovia from patients who smoked.
However, IL17A gene expression was lower in synovia from smokers. TBX21 and FOXP3 expression was not affected
by smoking. Within the synovial tissues of smokers the principal cell type with evidence of AHR activation was a
subset of synovial DCs. This observation was consistent with the sensitivity of human mo-DCs to BaP stimulation
demonstrated in vitro. Exposure to BaP affected mo-DC function as demonstrated by decreased IL6 expression
induced by PolyI:C, without affecting indoleamine 2,3 dioxygenase (IDO)1 expression.
Conclusion: Our findings show that one effect of smoking on inflamed rheumatoid synovial tissue involves
activation of the AHR pathway. A subset of synovial DCs is important in the response to cigarette smoke. The
potential for smoking to affect DC behaviour in joint tissues has relevance to both early and late phases of RA
pathogenesis and warrants further investigation.
Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune dis-
ease predominantly manifest as polyarthritis but with
extra-articular complications such as rheumatoid nodules
(granulomas) in more severe cases. Clinical evidence
points to an effect of smoking on the severity of estab-
lished RA. Patients with RA who continue to smoke
cigarettes have higher disease activity and develop worse
disability [1,2]. They have a greater requirement for
treatment with disease-modifying antirheumatic drugs
(DMARDs) [3] and respond less well to anti-TNF agents
[4,5]. Smokers with RA are also less likely to achieve sus-
tained DMARD-free remission than non-smokers [6].
Interactions between genetic pre-disposition and envir-
onmental factors have been identified as important in
determining the risk of developing RA. Approximately
50% of the risk is attributable to genetic factors with
HLA-DRB1 shared epitope (SE) alleles the major genetic
determinants of RA susceptibility [7,8] and severity
[9,10]. Other genetic risk loci particularly associated with
the development of anti-citrullinated peptide antibody
(ACPA)-positive RA, include genes that influence T cell
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function and the handling of arthritogenic antigens
[11-13].
Epidemiologic data has established cigarette smoking as
an important environmental factor that interacts power-
fully with the SE to increase the risk for development of
RA [14-16]. Smoking is associated with increased produc-
tion of autoantibodies, including ACPA and rheumatoid
factor (RF) and with increased incidence of extra-articular
manifestations in RA that include the development of
rheumatoid nodules [16,17]. Biologic mechanisms that
explain the epidemiologic data and accommodate an influ-
ence of the SE are increasingly understood [15,18,19]. One
aspect is that smoking enhances the expression of peptidy-
larginine deiminase and consequently increases the gen-
eration of citrullinated protein(s) within the lung alveolar
compartment [20]. There is evidence that antibodies react-
ing with citrullinated whole proteins, contribute to the
pathogenesis of RA. These include antibodies to citrulli-
nated fibrinogen or collagen type II that are involved in
immune-complex mediated inflammation as well as anti-
bodies to citrullinated a-enolase, which are particularly
associated with SE+ HLA-DRB1 alleles and that identify
patients with a higher frequency of joint erosions and RF
positivity [21-23]. Furthermore, T cells in RA patients also
respond to citrullinated aggrecan peptides [24]. Thus,
smoking and interactions between smoking and genetic
variants contribute to autoimmunity against post-transla-
tionally modified (citrullinated) peptides/proteins that are
important in the pathogenesis of RA [25].
Of further relevance is the potential for smoking to
influence T helper (Th)17 lymphocyte-mediated inflam-
mation. Polycyclic aromatic hydrocarbons (PAHs) are
amongst a number of compounds present in cigarette
smoke that activate the aryl hydrocarbon receptor (AHR),
a transcription factor that binds to xenobiotic response
elements (XRE) and regulates gene expression. Genes
encoding select members of the cytochrome P450 (CYP)
family of enzymes, (for example, CYP1A1), and the AHR
repressor (AHRR) are particularly responsive to ligand-
dependent AHR activation, a characteristic used to distin-
guish AHR activation. In vitro evidence shows that the
activation of AHR also promotes the differentiation of
Th17 lymphocytes and consequently the production of the
Th17-related cytokines, interleukin (IL)-17A, IL-17F and
IL-22 [26]. Experimental models of arthritis and clinical
indications have highlighted an important role for IL-17A
in the pathogenesis of RA [27-29]. Thus the AHR provides
another potential link between exposure to compounds in
cigarette smoke and the notable effect that smoking has
on rheumatoid inflammation. To address this possibility,
we set out to establish the presence of the AHR in the tis-
sues of patients with RA, to seek evidence for activation of
the AHR pathway in joint and extra-articular sites of
inflammation in smokers and non-smokers, and to
investigate corresponding levels of IL17A expression. Our
results indicate AHR activation in synovial tissue, asso-
ciated with smoking. Synovial dendritic cells are sensitive
to AHR ligand and in RA patients respond with activation
of the AHR. Contrary to expectation the activation of
AHR in synovial tissue was not associated with increased
IL-17A expression.
Materials and methods
Patients and tissue samples
Twenty synovial and eighteen nodule tissue samples
were obtained from 31 patients with RA. All patients
fulfilled American Rheumatism Association 1987 classi-
fication criteria for RA [30]. Patients were classified
according to their reported smoking habits as either: (i)
smokers (actively smoking when the tissue sample was
taken) - including those who were daily or non-daily
smokers of tobacco via cigarettes or loose tobacco; or
(ii) non-smokers - including ex-smokers (those who
ceased smoking ≥ 3 months prior to nodule samples or
≥ 8 years prior to synovial samples being taken), and
those who have never smoked tobacco in their lifetime.
The demographics of RA patients contributing synovial
and/or nodule tissue are summarised in Table 1. With
two exceptions, all RA patients included in this study
were SE+ (overall single copy of SE, n = 20 (65%); dou-
ble copy of SE, n = 9 (29%)).
Two synovial samples were available from three patients
(one smoker, two non-smokers), taken 6 months, 1 year
and 5 years apart respectively. Paired synovial and nodule
samples were obtained at the same time from four sepa-
rate patients (one smoker, three non-smokers).
Synovia from two patients with osteoarthritis (OA)
were also studied. One synovium (male patient, age 66
years) was processed commercially (Origene, Rockville,
Maryland, USA); the second synovium (female patient,
age 72 years) was sourced from tissue stocks. Their
smoking status is unknown.
Informed consent was obtained for the use of all patient
tissue, with the study approved by the New Zealand
Multi-Regional Ethics Committee. The use of peripheral
blood (PB) from normal healthy donors and associated
work involving PB leukocytes was approved by the Univer-
sity of Otago Ethics committee.
Isolation, culture, and stimulation of PB monocytes and
monocyte-derived dendritic cells (mo-DCs)
Peripheral blood mononuclear cells were isolated from
heparinized venous blood of healthy non-smoking human
donors by Ficoll density centrifugation. CD3+ T-cells,
CD20+ B-cells, and CD14+ monocytes were purified using
appropriate antibody-coated magnetic MACS® microbe-
ads and an AutoMacs separator (Miltenyi Biotec, Bergisch
Gladbach, Germany) according to the manufacturer’s
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instructions. Lymphocytes were used without further
manipulation.
CD14+ monocytes were resuspended in RPMI 1640
medium supplemented with 10% fetal calf serum, 2mM
glutamine, 50 U/ml penicillin, 50 μg/ml streptomycin
(complete medium) and were stimulated with varied con-
centrations (0.001μM to 10 μM) of benzo(a)pyrene (BaP)
or equivalent dimethyl sulfoxide (DMSO) alone (control)
for 24 hr. Stimulation with BaP, a polycyclic aromatic
hydrocarbon present in cigarette smoke mimicked the
effect of smoke. Alternatively, mononcytes were stimu-
lated with 10μM phorbol 12-myristate 13-acetate (PMA)
in complete medium for 72 hr at 37ºC and 5% CO2.
Mo-DCs were generated from CD14+ monocytes by
culture in complete medium with recombinant human
granulocyte macrophage colony-stimulating factor
(rhGMCSF), and rhIL-4 (each 25ng/ml; R&D Systems,
Minneapolis, Minnesota, USA) for 6 days at 37ºC and
5% CO2. Complete medium containing cytokines was
replenished on day 3. Mo-DCs were further treated with
either DMSO or 0.001μM to- 10 μM BaP in DMSO, or
with polyinosinic:polycytidylic acid (Poly I:C) (12.5μg/
ml) for 24 hr. Purity and maturation of DCs was
assessed by staining with monoclonal antibodies to
CD14, CD11c and CD83 (BD Biosciences, San Jose,
California, USA) and FACS analysis. Immature mo-DCs
were CD14-, CD11c+, CD83low and as expected became
CD14-, CD11c+, CD83high upon maturation induced by
Poly I:C stimulation.
Quantitation by real-time polymerase chain reaction
(RT-PCR)
Total RNA was purified from rheumatoid nodule and syno-
vial tissues or from cultured cells, and reverse transcribed
using Superscript III (Invitrogen, Carlsbad, California,
USA) as previously described [31]. Gene expression was
assessed by RT-PCR using SYBR Green or TaqMan gene
expression assays on an Applied Biosystems ABI 7300
sequence detection system. The SYBR Green primers (Invi-
trogen) were AHR (sense): 5’-TTC AGT TCT TAG GCT
CAG CGT -3’, AHR (antisense): 5’-TGC TGC TCT ACA
GTT ATC CTG G -3’ and GAPDH (sense): 5’- TGC ACC
ACC AAC TGC TTA GC -3’, GAPDH (antisense): 5’-
GGC ATG GAC TGT GGT CAT GAG -3’. Commercially
available Taqman assays (Applied Biosystems, Foster City,
California, USA) were used to measure CYP1A1
(Hs00153120_m1), AHRR (Hs01005075_m1), IL17A
(Hs00174383_m1), IL17F (Hs00369400_m1), IFNG
(Hs00174143_m1), IL22 (Hs01574154_m1), IL23A
(Hs00372324_m1), IL23R (Hs00332759_m1), FOXP3
(Hs00203958_m1), IL6 (Hs00985639_m1), IDO1
(Hs00984148_m1), TBX21 (Hs00203436_m1) and GAPDH
(Hs99999905_m1) gene expression. All samples were
assessed in triplicate. Samples were considered negative for
gene expression when threshold cycle (Ct) values were <40.
Positive, test sample Ct values were extrapolated to stan-
dard curves obtained from human tonsil or lung standards,
to calculate the mean amount of gene-specific RNA in each
sample. Results are expressed as the mean ± SEM ng RNA
for each gene of interest, relative to the expression of gly-
ceraldehede-3-phosphate dehydrogenase (GAPDH) RNA.
Double immunofluorescence
Seven-μm sections of frozen synovial tissues were cut and
fixed in acetone for 10 minutess at 4ºC. After blocking
with 5% goat immunoglobulins (IgGs; Sigma, Saint Louis,
Missouri, USA) for 30 minutes at room temperature, the
sections were incubated separately with cell-specific
mouse monoclonal anti-CD3 (T cells; clone UCHT1),
anti-CD20 (B cells; clone L26; DAKO, Glostrup, Den-
mark), anti-CD14 (monocytes/macrophages; clone FMC-
17), anti-DCs (clones CMRF44 [32] and CMRF56 [33,34]),
anti-CD303(BDCA-2) (pDCs; clone AC144; Miltenyi
Biotec), anti-CD1 (imDC; clone Na134), or anti-prolyl 4-
hydroxylase (fibroblast; clone 5B5; Abcam, Cambridge,
UK) overnight at 4ºC, followed by incubation with
Table 1 Patient demographics and clinical data
Synovia Nodules
Smokers(n = 6*) Non-smokers(n = 11*) Smokers(n = 4) Non-smokers(n = 14)
Female, % 83 64 100 71
Age, years** 58 (37-79) 55 (35-74) 47 (44-50) 61(48-77)
Disease duration, years** 11 (2-30) 18 (3-30) 19 (13-30) 19 (2-44)
Nodules, n 5 (83%) 9 (82%) 4 (100%) 14 (100%)
Erosions, n 6 (100%) 10 (91%) 4 (100%) 13 (93%)
RF positive, n 6 (100%) 10 (91%) 4 (100%) 13 (93%)








ESR** 34 (3-85) 33 (13-64) 30 (13-64) 33 (6-54)
* Three patients (one smoker, two non-smokers) provided two synovial samples. ** mean values with the range in parenthesis. †For some patients, tissue samples
pre-dated the availability of tests for anticitrullinated peptide antibody (ACPA); †† Mean values ± SEM. Mean ACPA titers were not significantly different. n,
number of patients; RF, rheumatoid factor; SEM, standard error of the mean,]; ESR, erythrocyte sedimentation rate.
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AlexaFluor568-conjugated goat anti-mouse antibody
(diluted 1:1500; Invitrogen) for 1.5 hr at 4ºC. The sections
were then blocked with 5% mouse IgGs for 30 minutes at
room temperature following by incubation with biotiny-
lated mAbs either against AHR (clone RPT9; Abcam) or
CYP1A1 (clone b-2; Santa Cruz Biotechnology, Santa
Cruz, California, USA) overnight, at 4ºC with subsequent
incubation with AlexaFluor488-conjugated streptavidin
(10μg/ml; Invitrogen) for 30 minutes, at RT. Cell nuclei
were identified by counterstaining with Hoechst 33342
(2.5 μg/ml). Negative controls included the omission of
primary antibodies and substitution of primary antibodies
with mouse-named IgGs (DAKO). Co-localization of
fluorescent staining was assessed by epifluorescence
microscopy using a Zeiss microscope fitted with SpotRT
digital camera and imaging software (Diagnostic Instru-
ments, Sterling Heights, Michigan, USA). All samples
were assessed by a single observer (MK) in a blinded fash-
ion and verified by a second observer (PAH).
Statistical analysis
Differences in gene-expression levels were analyzed by
the Mann-Whitney U-test. Where appropriate data was
log transformed to stabilise the variance. The one-way
analysis of variance (ANOVA) multirange post hoc
Tukey’s test was used when multiple comparisons were
analyzed. Fisher’s exact probability test was used to mea-
sure association. Correlation coefficients were deter-
mined by rank correlation using a nonparametric
Spearman test. Analyses were done using Prism for
Windows v4.03 (GraphPad Software Inc, San Diego,
California, USA) or STATA11 statistical software. A
probability level of 5% was considered significant for all
statistical analysis.
Results
Smoking contributes to AHR activation in inflamed
synovial tissue
AHR expression was present in both synovial tissues and
nodules. Expression was higher in synovia (7.00 ± 1.12 ng
RNA, n = 20) compared to nodules (2.76 ± 0.37 ng RNA,
n = 18, P < 0.0006) (Figure 1A), but these levels of AHR
expression in inflamed rheumatoid tissues were not
affected by smoking (Figure 1B).
Expression of the prototypic AHR responsive gene,
CYP1A1 was used to establish the activation status of
AHR in synovial and nodule tissues. CYP1A1 transcript
was detected in 7/20 synovial membranes (35% CYP1A1+)
and in 7/18 nodules (39% CYP1A1+). We considered
whether smoking was a factor influencing the activation of
AHR, reflected by the CYP1A1 expression. We found six
of the 7 CYP1A1+ synovia were from smokers, whereas
12/13 CYP1A1- synovia were from patients who were
non-smokers. The association between patients who
smoke and the activation of AHR was significant
in inflamed synovium (Fisher’s exact test, P = 0.005)
(Table 2) but was not evident in the separate cohort of 18
patients who provided nodule tissues (Table 2).
Levels of CYP1A1 expression were also significantly
higher in synovial tissues from RA patients who smoked
compared to non-smokers (0.048 ± 0.011 vs. 0.003 ±
0.003 ng RNA respectively, P = 0.004). There was no
such difference in nodule tissues (0.21 ± 0.12 vs. 0.27 ±
0.25 ng RNA, Figure 1C). Similarly, expression of the
AHRR gene, which also depends on AHR activation and
consequent transcription activity [35], was significantly
higher in synovial tissues from RA patients who smoked
when compared to non-smokers (1.79 ± 0.48 vs. 0.53 ±
0.21 ng RNA, P = 0.036); this was not the case in nodule
tissues (4.82 ± 3.41 vs. 1.78 ± 0.95 ng RNA respectively,
Figure 1D). There was a statistically significant positive
correlation between CYP1A1 and AHRR expression in
synovial tissues (Spearman r = 0.71, P = 0.0005) that also
occurred in nodules (Spearman r = 0.62, P = 0.0062, data
not shown).
Variable expression of AHR was also observed in syno-
via from separate patients with OA. Expression levels
overlapped with the range established for rheumatoid
synovia (Figure 1E). Irrespective of the extent of AHR
expression, CYP1A1 expression was not detected in OA
synovia.
Possible long-term effect of smoking on AHR expres-
sion and activation within synovial tissue was considered.
Three patients providing four synovial samples were ex-
smokers, having ceased smoking ≥ 8 years prior. Levels
of synovial AHR expression were equivalent between
patients who were smokers (n = 7), ex-smokers (n = 4)
and those who had never smoked (n = 9), consistent with
a lack of effect from smoking on AHR expression (Addi-
tional file 1). CYP1A1 expression was not detectable in
ex-smokers, suggesting no long-term effect from smoking
on AHR activation (Additional file 1).
Inflammatory genes that reflect the downstream
influence of AHR-activation
We further considered the implications of smoking for
the expression of a number of immuno-inflammatory
genes implicated in RA. Experimentally, Th17 cells are a
direct cellular target of AHR agonists [26]. Their signa-
ture cytokine, IL-17A has been implicated in the patho-
genesis of RA [36]. As such, Th17 cells provide a
possible link between smoking, AHR activation and the
exacerbation of synovial inflammation in RA. However,
we found significantly less IL17A gene expression in
synovial tissue from smokers when compared to non-
smokers (Figure 2) and a negative association between
IL17A and CYP1A1 gene expression (Spearman r =
-0.51, P = 0.022).
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Amongst other Th17 cell cytokines, expression of the
IL17F gene was not affected by smoking but was
restricted to CYP1A1- synovia, whereas IL22 gene
expression was not detected in any synovia (data not
shown). We also considered the potential for smoking
to impact upstream of IL17A but found no evidence of
an impact on gene expression of the critical cytokine
IL23, nor of the IL23 receptor (IL23R). Similarly, smok-
ing had no effect on Th1-cell mediated inflammation via
interferon-g (IFNG), T-bet (TBX21) or FOXP3 gene
expression in synovia (Figure 2).
Human DCs are implicated in the response of inflamed
synovial tissue to smoking
Next we sought to identify the cell type(s) expressing
AHR and showing AHR activation in inflamed synovial
tissues. Using double immunofluorescence staining,
CYP1A1 protein was observed only in CYP1A1+ synovia
from RA patients who were smokers. In these synovia,
both AHR and CYP1A1 proteins were produced by early
differentiating CMRF44+ and CMRF56+ DCs (Figure 3A,
B, C). These AHR+/CYP1A1+ DCs were mainly observed
in close proximity to T and B cells (data not shown).
Staining for AHR was cytoplasmic and in some DCs
more obviously perinuclear, with small amounts of AHR
protein localized within the nucleus, consistent with
AHR activation (Figure 3B). Amongst the other cell types
Figure 1 Aryl hydrocarbon receptor (AHR) expression and activation in inflamed rheumatoid tissues. (A) Overall AHR expression in
synovial tissues (closed circles, n = 20) and nodule tissues (closed squares, n = 18). (B) AHR, (C) CYP1A1 and (D) AHR receptor (AHRR) expression
in synovial tissues from rheumatoid arthritis (RA) patients who smoked (closed circles, n = 7) and non-smokers (open circles, n = 13), and nodule
tissues of RA patients who smoked (closed squares, n = 4) and non-smokers (open squares, n = 14). (E) AHR and CYP1A1 expression in synovia
from two separate patients with osteoarthritis (OA), labelled P1 and P2. n.d., not detected. Data are mean ± standard error of the mean (SEM).
All mRNA levels are expressed relative to glyceraldehede-3-phosphate dehydrogenase (GAPDH). ***P < 0.001; **P < 0.01; *P < 0.05, Mann-
Whitney U-test.
Table 2 Patient smoking status and tissue aryl





Synovia CYP1A1+ 6† 1
CYP1A1- 1 12†
0.005
Nodules CYP1A1+ 2 4
CYP1A1- 2 10
0.57
*Patient smoking status when tissue sample was taken; †Patients contributing
paired samples were considered once for statistical analysis; ‡P-value obtained
by Fisher’s exact probability two-tailed test
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examined, rare (much less than 1%) CD3+ T cells pro-
duced AHR and CYP1A1 proteins (Figure 3D, E).
Although most CD303+ plasmacytoid DCs (pDCs) pro-
duced AHR protein, only occasional CD20+ B cells were
AHR+ and neither pDCs nor B cells produced detectable
CYP1A1 protein. In synovium, immature CD1+ DCs,
CD14+ monocyte/macrophages and fibroblasts expres-
sing prolyl-4-hydroxylase did not express either AHR or
CYP1A1 protein (data not shown).
AHR or CYP1A1 protein was not detected in nodule
lesions, regardless of smoking status (data not shown).
Human mo-DCs are highly sensitive to AHR stimulation
with BaP
Finally we questioned the type(s) of cells that respond to
AHR ligands with evidence of AHR activation. We found
comparable AHR gene expression in T and B cells and
monocytes from normal human PB cells and in mo-DCs
(Figure 4A). Monocytes showed no significant change in
AHR or CYP1A1 expression when exposed to increasing
concentrations of the AHR agonist, BaP (Figure 4B,C). In
contrast, mo-DCs were extremely sensitive to BaP. The
inducing effect of BaP upon CYP1A1 expression in mo-
DCs was evident at 0.1 μM and maximal at BaP concen-
trations of 1-10μM (Figure 4B, D), eliciting an average
30-fold increase in CYP1A1 expression (Figure 4D).
When compared to untreated cells we observed no effect
on AHR or CYP1A1 expression in PMA-treated mono-
cytes (Figure 4C) or when mo-DC maturation was
induced by PolyI:C (Figure 4D).
We sought evidence for a possible mechanism linking
smoking, DC function and the effect on IL17A expres-
sion. Significant IL6 gene expression was a feature of
mo-DCs induced to mature via PolyI:C stimulation (Fig-
ure 4E). This expression was inhibited by the AHR ago-
nist, BaP (Figure 4E). Significant IDO1 expression was
also a feature of PolyI:C-induced mo-DC maturation.
However this expression was not affected by BaP (Fig-
ure 4F).
Discussion
It is now well established that interactions between
smoking and the SE increase the risk of developing RA
[37] through effects mediated in the early pre-clinical
stage of RA [38,39]. There are also indications that in
established RA smoking is associated with more active
disease and worse outcomes [20,21]. We hypothesized
that in established RA, products within cigarette smoke,
such as PAHs, may act upon the AHR, resulting in acti-
vation and downstream pro-inflammatory effects. In vitro
work has suggested that this might include activation of
Th17 cells, a pathway established as important to promo-
tion of inflammation and joint damage in RA. We there-
fore sought evidence for AHR expression in RA lesions,
the activation of AHR, and cells that showed evidence of
AHR-mediated activation.
In advanced, erosive RA, we demonstrated AHR
expression in both synovial and subcutaneous nodule tis-
sues. There was significantly more AHR gene expression
in synovial membrane but this expression was not
affected by smoking. The nodule and synovium are dif-
ferent inflammatory lesions with respect to the composi-
tion of the cellular infiltrate. Subcutaneous nodules are
granulomas, dominated by monocyte/macrophages but
our data suggest that the difference in AHR gene expres-
sion is not entirely due to this difference in inflammatory
cell type. Limited analysis of synovia from patients with
OA also indicated AHR expression suggesting that
inflammation, particularly associated with RA, is not
entirely responsible for upregulated AHR expression.
Only in synovial tissue did we find evidence that smok-
ing causes significant AHR activation, reported by
increased expression of both the CYP1A1 and AHRR
genes. Amongst patients who smoked, the majority
showed this pattern of AHR-mediated activation. While
was little evidence of AHR activation in synovium from
non-smokers, there was also no indication that AHR
expression or activation in synovia from ex-smokers was
different from patients who had never been smokers.
Any evidence of AHR activation within synovial tissue
was gone 8 to 33 years after ex-smokers ceased smoking,
suggesting no lasting impact of smoking on AHR-
mediated mechanisms. Such a finding is at odds with the
long-term effect of smoking on the risk of developing RA
[8] and indicates that the activation of AHR by current
smoking might be more important to ongoing synovial
inflammation and thereby contribute to the severity of
Figure 2 The effect of smoking on immune-inflammatory gene
expression levels in rheumatoid arthritis (RA) synovia. The
figure shows mean gene expression levels ± standard error of the
mean (SEM) in synovia obtained from patients with RA who smoked
(solid bars) compared to non-smokers (open bars). All mRNA levels
are expressed relative to glyceraldehede-3-phosphate
dehydrogenase (GAPDH). *P < 0.05, Mann Whitney U-test.
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established RA. Consistent with this, a recent report also
distinguishes an effect from current smoking, manifest as
a reduced chance of response to methotrexate and to
TNF inhibitor treatment. This compares with past smok-
ing, which has no such influence on treatment [40]. Thus
the risk of RA from smoking likely relates to a mechan-
ism(s) independent of continued AHR activation.
The situation in nodules is more complex. In nodule
tissues we found generally higher levels of CYP1A1 gene
expression but were unable to demonstrate CYP1A1 pro-
tein. However, the most important observation was that
CYP1A1 gene expression in nodules was independent of
current smoking status or smoking history. This suggests
an alternative (possibly endogenous) AHR ligand within
these lesions, the nature of which remains to be deter-
mined. It suggests that the AHR-mediated response to
cigarette smoke may be most pronounced in the inflamed
synovium in patients with RA. Whether this is a unique
aspect of RA remains to be established. Synovia from OA
patients were CYP1A1-negative regardless of AHR
expression levels. Unfortunately, details of these patients’
smoking status were unavailable.
While our data indicate smoking has a molecular
impact within inflamed rheumatoid synovium, a critical
question is how any AHR-mediated mechanism might
influence the inflammatory process. We addressed this
Figure 3 Human dendritic cells (DCs) are the principal cells implicated in response to smoking. Double immunofluorescence staining of
synovial tissue for (A) aryl hydrocarbon receptor (AHR) protein (green) in CMRF44+ (red, top panels) or CMRF56+ DCs (red, bottom panels). (B)
Enlarged images show cytoplasmic and nuclear localization of AHR (green) staining in CMRF44+ (red, top panels) or CMRF56+ DCs (red, bottom
panels) as indicated. (C) CYP1A1 protein (green) in CMRF44+ (red, top panels) or CMRF56+ DCs (red, bottom panels). (D) AHR and (E), CYP1A1
protein (green) in CD3+ T cells (red). In all images, nuclei are counterstained with Hoechst (blue). Scale bar, 20 μm.
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Figure 4 Increased sensitivity of monocyte-derived dendritic cells (mo-DCs) to benzo(a)pyrene (BaP) stimulation. (A) The expression of
aryl hydrocarbon receptor (AHR) and CYP1A1 in human peripheral blood (PB) CD3+ T cells, CD20+ B cells, CD14+ monocytes and mo-DCs. Gene
expression was analyzed using qRT-PCR. All mRNA levels are expressed relative to glyceraldehede-3-phosphate dehydrogenase (GAPDH). Data
are the mean ± standard error of the mean (SEM) (n = 2). (B) Comparison of the dose-dependent response of CD14+ monocytes and mo-DCs to
(0.01-10μM) BaP stimulation (24 hr). Data are representative of three experiments with cells purified or derived from the same PB sample.
Comparison of AHR and CYP1A1 gene expression in (C) CD14+ monocytes and (D) mo-DCs when stimulated with varied concentrations (1 -
10μM) of BaP (24 hr), 10μM phorbol 12-myristate 13 acetate (PMA) (72 hr; monocytes), or polyinosinic:polycytidylic acid (PolyI:C) (24 hr; mo-DCs)
treatment. Data are the mean ± SEM (n = 3) relative to AHR and CYP1A1 mRNA levels found in untreated cells (UNT), arbitrarily set at a value of
1 with cells purified or derived from the same PB sample. (E) Expression of IL6 and (F) IDO1 in response to 3μM BaP (24 hr) or PolyI:C (24 hr)
alone, or in combination (as indicated). n.d., not detected. Data are the mean SEM from 3 experiments. *P < 0.05, **P < 0.01, Tukey multiple
comparison test.
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question by identifying the cell types within synovium
that showed evidence of AHR activation. We found that
a subset of CMRF56+ and/or CMRF44+ DCs within
inflamed synovia were the predominant cells that
expressed both AHR and CYP1A1 protein. There were
also very occasional T cells and plasmacytoid DCs and,
even more rarely, B cells in these synovia that expressed
AHR protein. Amongst these non-DC types, only the
T cells showed evidence of AHR activation through
CYP1A1 protein expression. In situ, these T cells were
rare, even in synovia where generalized T cell infiltration
was prominent. Synovial monocyte/macrophages were
negative for both AHR and CYP1A1 protein. Clearly
AHR+/CYP1A1+ DCs within the synovium display mar-
kers characteristic of early differentiating/activated DCs.
The data highlight these cells as a potential focal point
for the effects of cigarette smoke components within tis-
sues and subsequent immune/inflammatory outcomes.
We considered further detail of mechanisms potentially
utilized by DCs in response to AHR agonists. For this we
used BaP, an AHR agonist that can be metabolized and is
a known component of cigarette smoke [41]. When com-
pared to paired PB CD14+ monocytes, mo-DCs responded
to lower concentrations of BaP in vitro, with AHR activa-
tion that culminated in significantly greater CYP1A1
expression at higher BaP concentrations. Thus, DCs are
more sensitive to BaP, an observation that is consistent
with these being the most commonly observed cells show-
ing evidence of AHR activation in the inflamed synovial
tissue. Similarly, the insensitivity of monocytes to BaP is
consistent with the lower AHR gene expression and activa-
tion, and lack of detectable protein observed in monocyte/
macrophage-dominated nodules. There are known
immune/inflammatory consequences of DCs responding
in such a sensitive manner to AHR agonists. In murine
systems AHR activation can directly affect the differentia-
tion and innate immune functions of inflammatory DCs
without affecting their ability to interact with T cells
[42,43]. Overall the studies in mice suggest AHR-mediated
mechanisms influence the regulatory activities of DCs
with consequences that skew naïve T cell differentiation
towards Treg cells and away from Th17 cells. Such a
response would be expected to limit immune/inflamma-
tory activity [44,45]. We observed reduced expression of
IL17A in synovia from RA patients who smoked, a nega-
tive correlation between IL17A expression and AHR acti-
vation in synovia, and expression of IL17F that was limited
to CYP1A1- synovia. All are consistent with an effect of
smoking on Th17 cell systems that involves AHR activa-
tion within intermediary DCs, rather than a direct effect
on actual Th17 cells. As discussed, there was limited evi-
dence of synovial T cells responding directly to smoking.
There was no change in the presence of regulatory T cells
(measured as FOXP3 expression), Th1 cells or Th1-like,
ex-Th17 cells (TBX21/T-bet and IFNG expression) produ-
cing interferon-g [46] between synovia from smokers and
non-smokers. While expression of the IL6 and IL23 genes
was not significantly different between these synovia, the
data were indicative of some effect on IL6 from current
smoking. This possibility was strengthened by in vitro data
showing that BaP exposure inhibits IL6 expression by
PolyI:C-stimulated mo-DCs. In this manner a critical regu-
latory signal, operative at the DC-T cell interface, could be
affected by AHR activation in DCs, ultimately influencing
DC control of T cells. Our data are consistent with this
control negatively impacting on Th17 cells. We cannot
exclude direct effects on T cells suggested by the rare
AHR+ T cells observed in synovia.
Such effects on potential or relevant pathogenic
mechanisms contrast with epidemiological evidence show-
ing increased risk of disease and worse inflammation in
patients with RA who smoke. Interactions between smok-
ing and the presence of SE+ HLADRB1 alleles offer some
explanation for this anomaly. All patients in our study
were SE+ thereby precluding detailed comparison of SE
presence or copy number. Preliminary analysis, including
this patient cohort, suggests an opposing effect of smoking
and SE copy number on synovial IL17A expression.
In summary we have demonstrated the presence of the
AHR receptor within synovial tissue from patients with
RA, with the potential to interact with polycyclic aromatic
hydrocarbons in cigarette smoke. We have found evidence
for activation via the AHR with increased levels of
CYP1A1 and AHRR in synovial tissues from patients who
continue to smoke. Based on in vitro data, we considered
that such AHR activation, mediated by products in cigar-
ette smoke, might activate Th17 cells. In contrast to this
we found decreased expression of IL17, and that the pre-
dominant cell activated was the DC. Indications are that
reduced IL6 expression by DCs is a possible consequence
of cigarette smoke exposure, a factor that subsequently
impacts negatively on IL17A expression.
Conclusions
Our data suggests that cigarette smoke-induced changes in
DC responses have the potential to be relevant to both the
early pre-clinical phase of RA and the later stages of the
disease. In the pre-clinical phase it is thought that antigen-
presenting cells that express the shared epitope preferen-
tially interact with post-translationally altered citrullinated
antigens. Smoking is thought to act through promoting
the citrullination of relevant antigens. Our data suggest
that smoking might also act by altering DC responses.
This effect on DCs could also be relevant to the influence
of smoking on inflammation in established RA. Further
detail of the effects of smoking on DC has the potential to
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provide further insights into mechanisms relevant to both
the early induction phase of RA and worsening of estab-
lished RA.
Additional material
Additional file 1: Long-term effect of smoking on aryl hydrocarbon
receptor (AHR) expression and activation in synovial tissues. Shown
is any effect from current smoking or former smoking on AHR expression
and CYP1A1 gene expression in joint synovial tissue from RA patients.
Comparisons are made with data from non-smokers. There is no
significant difference in synovial AHR expression between RA patients
who are current smokers, ex-smokers or non-smokers. The expression of
CYP1A1, reflecting AHR activation, is significantly different only in
rheumatoid arthritis (RA) patients who continue to smoke.
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